REGN vs VRTX
Regeneron Pharmaceuticals and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $115B against $64B. On trailing earnings REGN is the cheaper of the two at a P/E of 18.4 against 29.7, a gap that is only a bargain if the two are growing at similar rates. Over the past year VRTX returned +32% against +25% for REGN. The RyuScore puts REGN ahead, 70 against 59 out of 100.
| Figure | REGN | VRTX |
|---|---|---|
| Last close | $746 | $510 |
| Market cap | $64B | $115B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.4 | 29.7 |
| 1-year return | +25% | +32% |
| 5-year return | +18% | +168% |
| RyuScoresector-relative, 1–10 | 70/100 | 59/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit Losses, 50% of the disclosed total.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 75% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.